Published: Guidance, quality standards and advice

Skip to filtersSkip to results

Skip to results

Keyword or reference number

Keyword or reference number

Last updated date

Last updated date

Area of interest

Area of interest

Type

Type

Guidance programme

Advice programme

Showing 271 to 280 of 1535

TitleReference numberPublishedLast updated
Olaparib for adjuvant treatment of BRCA mutation-positive HER2-negative high-risk early breast cancer after chemotherapyTA886
Olaparib for previously treated BRCA mutation-positive hormone-relapsed metastatic prostate cancerTA887
Point-of-care tests for urinary tract infections to improve antimicrobial prescribing: early value assessmentHTE7
Ripretinib for treating advanced gastrointestinal stromal tumour after 3 or more treatmentsTA881
Voclosporin with mycophenolate mofetil for treating lupus nephritisTA882
Tafasitamab with lenalidomide for treating relapsed or refractory diffuse large B-cell lymphomaTA883
Capmatinib for treating advanced non-small-cell lung cancer with MET exon 14 skipping (terminated appraisal)TA884
Metastatic malignant disease of unknown primary origin in adults: diagnosis and managementCG104
Fasciotens for abdominal wall closureMIB321
Tezepelumab for treating severe asthmaTA880

Results per page

  1. 10
  2. 25
  3. 50
  4. All